Journey Medical (DERM) Company Report

Journey Medical reported total revenues of $17.6 million in Q3 2025, marking a 21% increase year-over-year. This growth was significantly boosted by Amrosi, which contributed $4.9 million and experienced a 75% increase in revenue compared to Q2 2025.
The company achieved positive adjusted EBITDA of $1.7 million for Q3 2025, up from $300,000 in Q3 2024, and anticipates becoming sustainably EBITDA positive in Q4 2025.
Amrosi's launch demonstrated strong momentum, with total prescriptions growing 146% to 18,198 in Q3 2025 from 7,394 in Q2 2025, and unique prescribers increasing by 50% to over 2,700.
Journey Medical concluded Q3 2025 with $24.9 million in cash and cash equivalents.

Nov 12, 2025, 9:30 PM

Journey Medical Reports Q3 2025 Financial Results

DERM

Earnings

Revenue Acceleration/Inflection

Product Launch

Journey Medical Corporation reported net revenues of $17.6 million for the third quarter of 2025, representing a 21% increase compared to the third quarter of 2024.
Emrosi™ generated $4.9 million in net revenues, with total prescriptions increasing 146% over the second quarter of 2025, supported by expanded payer access to over 100 million commercial lives.
The company's net loss for the third quarter of 2025 was $2.3 million, an improvement from a $2.4 million net loss in the prior-year quarter, and Adjusted EBITDA was a positive $1.7 million.
As of September 30, 2025, cash and cash equivalents totaled $24.9 million, an increase from $20.3 million at December 31, 2024.

Nov 12, 2025, 9:07 PM

Journey Medical Corporation Reports Strong Q3 2025 Financial Results Driven by Emrosi Growth

DERM

Earnings

Product Launch

Revenue Acceleration/Inflection

Journey Medical Corporation reported net revenues of $17.6 million for the third quarter of 2025, marking a 21% increase compared to the third quarter of 2024.
Emrosi™ net revenues reached $4.9 million in Q3 2025, with total prescriptions growing 146% over the second quarter of 2025, supported by expanded payer access covering over 100 million commercial lives in the U.S..
The company's net loss for the third quarter of 2025 was $2.3 million, or $(0.09) per share, an improvement from a net loss of $2.4 million, or $(0.12) per share, in the third quarter of 2024.
Adjusted EBITDA for Q3 2025 was a positive $1.7 million, up from $0.3 million in the prior-year quarter, and cash and cash equivalents totaled $24.9 million as of September 30, 2025.

Nov 12, 2025, 9:01 PM

Journey Medical Corporation enters new At Market Issuance Sales Agreement and terminates previous one

DERM

Journey Medical Corporation entered into a new At Market Issuance Sales Agreement on August 28, 2025, allowing it to sell up to 3,750,000 shares of its common stock through B. Riley Securities, Inc. and Lake Street Capital Markets, LLC.
The company will pay each agent a commission of 3.0% of the gross proceeds from sales under this new agreement.
This new agreement replaces a previous At Market Issuance Sales Agreement with B. Riley, which was terminated effective August 28, 2025.
Under the terminated agreement, the company sold 4,121,318 shares of common stock between December 30, 2022, and August 28, 2025.